Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: Results of a double-blind, randomised placebo-controlled trial

Annals of the Rheumatic Diseases

Volumn 72, Issue 2, 2013, Pages 179-186

  Reginster, Jean Yves ^a   Badurski, Janusz ^b   Bellamy, Nicholas ^c   Bensen, William ^d   Chapurlat, Roland ^e   Chevalier, Xavier ^f   Christiansen, Claus ^g   Genant, Harry ^h   Navarro, Federico ⁱ   Nasonov, Evgeny ^j   Sambrook, Philip N ^k   Spector, Timothy D ^l   Cooper, Cyrus ^m  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Centre of Osteoporosis and Osteoarticular Diseases   (Poland)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITÉ DE LYON   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^h SYNARC INC   (United States)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^j V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^k ROYAL NORTH SHORE HOSPITAL   (Australia)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ANALGESIC AGENT; ANILIDE; CHONDROITIN SULFATE; CORTICOSTEROID; GLUCOSAMINE; PLACEBO; PROPIONIC ACID DERIVATIVE; STRONTIUM RANELATE;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EOSINOPHILIA; FEMALE; HUMAN; JOINT CAVITY; JOINT DEGENERATION; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ALLERGY; SYSTEMIC DISEASE; VENOUS THROMBOEMBOLISM; VOMITING; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

AGED; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOARTHRITIS, KNEE; THIOPHENES; TREATMENT OUTCOME;

EID: 84872091677     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202231     Document Type: Article

References (40)

1. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377:2115-26.
2. Cooper C, Arden NK. Excess mortality in osteoarthritis. BMJ 2011;342:d1407.
3. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-99.
4. Tat SK, Pelletier JP, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodelling in human osteoarthritic subchondral bone osteoblasts. Bone 2011;49:559-67.
5. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001;16:299-308.
6. Gulhan I, Bilgili S, Gunaydin R, et al. The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study. Arch Gynecol Obstet 2008;278:437-41.
7. Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9.
8. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
9. Kellgren MJ. The epidemiology of chronic rheumatism: atlas of standard radiographs. 2nd edn. Oxford, UK: Blackwell Scientific, 1963.
10. Cooper C, Reginster J-Y, Chapurlat R, et al. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of a randomised double-blind, placebo-controlled trial. Curr Med Res Opin 2012;28:231-9.
11. Kothari M, Guermazi A, von Ingersleben G, et al. Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis. Eur Radiol 2004;14:1568-73.
12. Gensburger D, Roux JP, Arlot M, et al. Influence of blinding sequence of radiographs on the reproducibility and sensitivity to change of joint space width measurement in knee osteoarthritis. Arthritis Care Res (Hoboken) 2010;62:1699-705.
13. Botha-Scheepers S, Watt I, Breedveld FC, et al. Reading radiographs in pairs or in chronological order influences radiological progression in osteoarthritis. Rheumatology (Oxford) 2005;44:1452-5.
14. Felson DT, Nevitt MC. Blinding images to sequence in osteoarthritis: evidence from other diseases. Osteoarthritis Cartilage 2009;17:281-3.
15. Gensburger D, Arlot M, Sornay-Rendu E, et al. Radiologic assessment of age-related knee joint space changes in women: a 4-year longitudinal study. Arthritis Rheum 2009;61:336-43.
16. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
17. Bingham CO III, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507.
18. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-121.
19. European Medicines Agency. Strontium ranelate. Summary of product characteristics. 2009. http://www.ema.europa.eu (accessed 12 Jun 2012).
20. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
21. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.
22. Deeks ED, Dhillon S. Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis. Drugs 2010;70:733-59.
23. European Medicines Agency. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. 2010. http://www.ema.europa.eu (accessed 12 Jun 2012).
24. Food and Drug Administration. Guidance for industry. Clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis. 2011. http://www.fda.gov (accessed 12 Jun 2012).
25. Montaseri A, Busch F, Mobasheri A, et al. IGF-1 and PDGF-bb suppress IL-1beta-induced cartilage degradation through down-regulation of NF-kappaB signaling: involvement of Src/PI-3K/AKT pathway. PLoS One 2011;6:e28663.
26. Tat SK, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24:51-70.
27. Atkins GJ, Welldon KJ, Halbout P, et al. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009;20:653-64.
28. Caverzasio J. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone 2008;42:1131-6.
29. Valdes AM, Spector TD. Genetic epidemiology of hip and knee osteoarthritis. Nat Rev Rheumatol 2011;7:23-32.
30. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
31. Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol 2000;27:1513-7.
32. Claessens AA, Schouten JS, van den Ouweland FA, et al. Do clinical findings associate with radiographic osteoarthritis of the knee? Ann Rheum Dis 1990;49:771-4.
33. Kahan A, Uebelhart D, De VF, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-33.
34. Bruyere O, Richy F, Reginster JY. Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Ann Rheum Dis 2005;64:1727-30.
35. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010;69:1459-64.
36. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23.
37. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
38. Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008;58:3183-91.
39. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-25.
40. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86.